Sort
82,697 grants matching “vaccine development”
Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain
$732,955Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2014 · AI
Mechanisms of vitamin A-dependent risk for tuberculosis progression and prevention
$732,939Brendan Podell · Colorado State University · R01 · FY2025 · AI
Small Molecule Protease Inhibitors against MERS-CoV
$732,873Kyeong-Ok Chang · Kansas State University · R01 · FY2020 · AI
Cellular Responses
$732,854David B. Weiner · Wistar Institute · U19 · FY2016 · AI
Allergen Loaded Nanoparticles for Food Allergy Tolerance
$732,841Lonnie D Shea · University Of Michigan At Ann Arbor · R01 · FY2024 · AI
Correlates of Vaccine-Induced, Tunable-Protection in an Outbred Tularemia Model
$732,824Karsten R.o. Hazlett · Albany Medical College · R01 · FY2017 · AI
Host Immune Responses to Antigens of Malaria Parasites
$732,813Carole Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Structural Vaccinology and Design of Novel Imunogens for Malaria Vaccine Development
$732,800Daniel E Goldberg · Washington University · R01 · FY2019 · AI
Systems Biology Core
$732,767Alan A Aderem · Scripps Research Institute, The · U19 · FY2015 · AI
Human Cytomegalovirus Entry into Cells Mediated by Pentamer and Trimer Complexes
$732,705David C. Johnson · Oregon Health & Science University · R01 · FY2023 · AI
The COVID-19 and Cancer Consortium (CCC19) Registry
$732,687Jeremy Lyle Warner · Rhode Island Hospital · U01 · FY2024 · CA
Development of a Human Hydrolase to Treat Cocaine Abuse and Overdose:Rat Models
$732,603William S Brimijoin · Mayo Clinic Rochester · R01 · FY2009 · DA
Delivery of Biological Therapeutics: Using Engineered Particles and Novel Deliver
$732,600Joseph M Desimone · Univ Of North Carolina Chapel Hill · DP1 · FY2012 · CA
Delivery of Biological Therapeutics: Using Engineered Particles and Novel Deliver
$732,600Joseph M Desimone · Univ Of North Carolina Chapel Hill · DP1 · FY2011 · OD
Neonatal, Lactation, and Child Health Outcomes Following RSV Vaccination During Pregnancy
$732,591Kristin Palmsten · Healthpartners Institute · R01 · FY2024 · HD
Adolescent Medicine Trials Unit (AMTU) Network for HIV/*
$732,555John Barringer Steever · Icahn School Of Medicine At Mount Sinai · U01 · FY2009 · HD
North-Central California-Center For AIDS Research
$732,522University Of California Davis · P30 · FY2003 · AI
Examining biomarkers and mechanisms of health disparities in sexual minority women
$732,519Kathryn Elizabeth Keenan · University Of Chicago · R01 · FY2019 · HL
Malaria Pathogenesis and Human Immunity
$732,493Rick Fairhurst · National Institute Of Allergy And Infectious Diseases · ZIA · FY2011 · AI
Antibody Landscape following Human Norovirus Infection and Vaccination
$732,472Ralph S Baric · Univ Of North Carolina Chapel Hill · R01 · FY2024 · AI
AKT as a Biomarker of Ovarian Cancer Progression and a Target for Therapy
$732,444Joseph Robert Testa · Fox Chase Cancer Center · P50 · FY2007 · CA
Investigating Interferon Antagonists in Delaying Innate Immune Responses to SARS-CoV-2
$732,439Susan C. Baker · Loyola University Chicago · R01 · FY2025 · AI
Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters
$732,434Petros C Karakousis · Johns Hopkins University · R01 · FY2020 · AI
Chicago D-CFAR
$732,407Alan L Landay · Rush University Medical Center · P30 · FY2012 · AI
Chemoenzymatic synthesis of bacterial polysaccharides
$732,340Hai Yu · University Of California At Davis · U01 · FY2019 · GM